Sfoglia per Autore
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy
2010 Metro, G.; Zheng, Z.; Fabi, A.; Schell, M.; Antoniani, B.; Mottolese, M.; Monteiro, A. N.; Vici, P.; Rivera, S. L.; Boulware, D.; Cognetti, F.; Bepler, G.
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer. Meta-analysis of randomized trials
2010 Cuppone, F.; Bria, E.; Giannarelli, D.; Vaccaro, V.; Milella, M.; Nistico, C.; Ruggeri, E. M.; Sperduti, I.; Bracarda, S.; Pinnaro, P.; Lanzetta, G.; Muti, P.; Cognetti, F.; Carlini, P.
Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer
2010 Milella, M.; Gelibter, A. J.; Pino, MARIA SIMONA; Bossone, G.; Marolla, P.; Sperduti, I.; Cognetti, F.
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: Meta-analysis of randomized clinical trials
2010 Loupakis, F.; Bria, E.; Vaccaro, V.; Cuppone, F.; Milella, M.; Carlini, P.; Cremolini, C.; Salvatore, L.; Falcone, A.; Muti, P.; Sperduti, I.; Giannarelli, D.; Cognetti, F.
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
2010 Garufi, C.; Torsello, A.; Tumolo, S.; Ettorre, G. M.; Zeuli, M.; Campanella, C.; Vennarecci, G.; Mottolese, Marcella; Sperduti, I.; Cognetti, F.
Large randomized study of thymosin α 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma
2010 Maio, M.; Mackiewicz, A.; Testori, A.; Trefzer, U.; Ferraresi, V.; Jassem, J.; Garbe, C.; Lesimple, T.; Guillot, B.; Gascon, P.; Gilde, K.; Camerini, Roberta; Cognetti, F.
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer
2010 Metro, Giulio; Giannarelli, Diana; Gemma, Donatello; Lanzetta, Gaetano; Ciccarese, Mariangela; Papaldo, Paola; Gamucci, Teresa; Lorusso, Vito; Mottolese, Marcella; Magnolfi, Emanuela; Cognetti, Francesco; Fabi, Alessandra
Chordoma. Clinical characteristics, management and prognosis of a case series of 25 patients
2010 Ferraresi, V.; Nuzzo, C.; Zoccali, C.; Marandino, F.; Vidiri, A.; Salducca, N.; Zeuli, M.; Giannarelli, D.; Cognetti, F.; Biagini, R.
Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
2010 Campanella, C.; Mottolese, Marcella.; Cianciulli, A.; Torsello, A.; Merola, R.; Sperduti, I.; Melucci, E.; Conti, S.; Diodoro, M. G.; Zeuli, M.; Paoletti, G.; Cognetti, F.; Garufi, C.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
2011 Chapman, Pb; Hauschild, A; Robert, C; Haanen, Jb; Ascierto, P; Larkin, J; Dummer, R; Garbe, C; Testori, A; Maio, M; Hogg, D.; Lorigan, P; Lebbe, C; Jouary, T; Schadendorf, D; Ribas, A; O'Day, Sj; Sosman, Ja; Kirkwood, Jm; Eggermont, Amm; Dreno, B; Nolop, K; Li, J; Nelson, B; Hou, J; Lee, Rj; Flaherty, Kt; Mcarthur, Ga; BRIM-3 Study, Group; Cognetti, F
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients. Meta-regression analysis of randomized trials
2011 Cuppone, F.; Bria, E.; Vaccaro, V.; Puglisi, F.; Fabi, A.; Sperduti, I.; Carlini, P.; Milella, M.; Nistico, C.; Russillo, M.; Papaldo, P.; Ferretti, G.; Aapro, M.; Giannarelli, D.; Cognetti, F.
Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
2011 Russillo, M.; Di Benedetto, A.; Metro, G.; Ferretti, G.; Papaldo, P.; Cognetti, F.; Mottolese, Marcella; Fabi, A.
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis
2011 Bria, E.; Milella, M.; Cuppone, F.; Novello, Sebastiano; Ceribelli, A.; Vaccaro, V.; Sperduti, I.; Gelibter, A.; Scagliotti, G. V.; Cognetti, F.; Giannarelli, D.
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care
2011 Fabi, A.; Di Benedetto, A.; Metro, G.; Perracchio, L.; Nistico, C.; Di Filippo, F.; Ercolani, C.; Ferretti, G.; Melucci, E.; Buglioni, S.; Sperduti, I.; Papaldo, P.; Cognetti, F.; Mottolese, Marcella
Emerging pathways and future targets for the molecular therapy of pancreatic cancer
2011 Vaccaro, V.; Melisi, D.; Bria, E.; Cuppone, F.; Ciuffreda, L.; Pino, M. S.; Gelibter, A.; Tortora, G.; Cognetti, F.; Milella, M.
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
2011 Metro, G.; Foglietta, J.; Russillo, M.; Stocchi, L.; Vidiri, A.; Giannarelli, D.; Crino, L.; Papaldo, P.; Mottolese, Marcella; Cognetti, F.; Fabi, A.; Gori, S.
Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy
2011 Vizza, E.; Pellegrino, A.; Milani, R.; Fruscio, R.; Baiocco, E.; Cognetti, F.; Savarese, A.; Tomao, Federica; Chen, C.; Corrado, G.
Brain metastases from solid tumors. Disease outcome according to type of treatment and therapeutic resources of the treating center
2011 Fabi, A.; Felici, A.; Metro, G.; Mirri, A.; Bria, E.; Telera, S.; Moscetti, L.; Russillo, Michelangelo; Lanzetta, G.; Mansueto, G.; Pace, A.; Maschio, M.; Vidiri, A.; Sperduti, I.; Cognetti, F.; Carapella, CARMINE MARIA
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy. An italian, multicenter, randomized phase III trial
2012 Cognetti, F.; Ruggeri, E. M.; Felici, A.; Gallucci, M.; Muto, G.; Pollera, C. F.; Massidda, B.; Rubagotti, A.; Giannarelli, D.; Boccardo, Francesco
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. Meta-analytical estimation and implications for therapeutic strategies
2012 Loupakis, F.; Cremolini, C.; Salvatore, L.; Schirripa, M.; Lonardi, S.; Vaccaro, V.; Cuppone, F.; Giannarelli, D.; Zagonel, V.; Cognetti, F.; Tortora, G.; Falcone, A.; Bria, E.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy | 2010 | Metro, G.; Zheng, Z.; Fabi, A.; Schell, M.; Antoniani, B.; Mottolese, M.; Monteiro, A. N.; Vici, P.; Rivera, S. L.; Boulware, D.; Cognetti, F.; Bepler, G. | |
| Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer. Meta-analysis of randomized trials | 2010 | Cuppone, F.; Bria, E.; Giannarelli, D.; Vaccaro, V.; Milella, M.; Nistico, C.; Ruggeri, E. M.; Sperduti, I.; Bracarda, S.; Pinnaro, P.; Lanzetta, G.; Muti, P.; Cognetti, F.; Carlini, P. | |
| Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer | 2010 | Milella, M.; Gelibter, A. J.; Pino, MARIA SIMONA; Bossone, G.; Marolla, P.; Sperduti, I.; Cognetti, F. | |
| Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: Meta-analysis of randomized clinical trials | 2010 | Loupakis, F.; Bria, E.; Vaccaro, V.; Cuppone, F.; Milella, M.; Carlini, P.; Cremolini, C.; Salvatore, L.; Falcone, A.; Muti, P.; Sperduti, I.; Giannarelli, D.; Cognetti, F. | |
| Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial | 2010 | Garufi, C.; Torsello, A.; Tumolo, S.; Ettorre, G. M.; Zeuli, M.; Campanella, C.; Vennarecci, G.; Mottolese, Marcella; Sperduti, I.; Cognetti, F. | |
| Large randomized study of thymosin α 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma | 2010 | Maio, M.; Mackiewicz, A.; Testori, A.; Trefzer, U.; Ferraresi, V.; Jassem, J.; Garbe, C.; Lesimple, T.; Guillot, B.; Gascon, P.; Gilde, K.; Camerini, Roberta; Cognetti, F. | |
| Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer | 2010 | Metro, Giulio; Giannarelli, Diana; Gemma, Donatello; Lanzetta, Gaetano; Ciccarese, Mariangela; Papaldo, Paola; Gamucci, Teresa; Lorusso, Vito; Mottolese, Marcella; Magnolfi, Emanuela; Cognetti, Francesco; Fabi, Alessandra | |
| Chordoma. Clinical characteristics, management and prognosis of a case series of 25 patients | 2010 | Ferraresi, V.; Nuzzo, C.; Zoccali, C.; Marandino, F.; Vidiri, A.; Salducca, N.; Zeuli, M.; Giannarelli, D.; Cognetti, F.; Biagini, R. | |
| Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab | 2010 | Campanella, C.; Mottolese, Marcella.; Cianciulli, A.; Torsello, A.; Merola, R.; Sperduti, I.; Melucci, E.; Conti, S.; Diodoro, M. G.; Zeuli, M.; Paoletti, G.; Cognetti, F.; Garufi, C. | |
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | 2011 | Chapman, Pb; Hauschild, A; Robert, C; Haanen, Jb; Ascierto, P; Larkin, J; Dummer, R; Garbe, C; Testori, A; Maio, M; Hogg, D.; Lorigan, P; Lebbe, C; Jouary, T; Schadendorf, D; Ribas, A; O'Day, Sj; Sosman, Ja; Kirkwood, Jm; Eggermont, Amm; Dreno, B; Nolop, K; Li, J; Nelson, B; Hou, J; Lee, Rj; Flaherty, Kt; Mcarthur, Ga; BRIM-3 Study, Group; Cognetti, F | |
| Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients. Meta-regression analysis of randomized trials | 2011 | Cuppone, F.; Bria, E.; Vaccaro, V.; Puglisi, F.; Fabi, A.; Sperduti, I.; Carlini, P.; Milella, M.; Nistico, C.; Russillo, M.; Papaldo, P.; Ferretti, G.; Aapro, M.; Giannarelli, D.; Cognetti, F. | |
| Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile? | 2011 | Russillo, M.; Di Benedetto, A.; Metro, G.; Ferretti, G.; Papaldo, P.; Cognetti, F.; Mottolese, Marcella; Fabi, A. | |
| Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis | 2011 | Bria, E.; Milella, M.; Cuppone, F.; Novello, Sebastiano; Ceribelli, A.; Vaccaro, V.; Sperduti, I.; Gelibter, A.; Scagliotti, G. V.; Cognetti, F.; Giannarelli, D. | |
| HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care | 2011 | Fabi, A.; Di Benedetto, A.; Metro, G.; Perracchio, L.; Nistico, C.; Di Filippo, F.; Ercolani, C.; Ferretti, G.; Melucci, E.; Buglioni, S.; Sperduti, I.; Papaldo, P.; Cognetti, F.; Mottolese, Marcella | |
| Emerging pathways and future targets for the molecular therapy of pancreatic cancer | 2011 | Vaccaro, V.; Melisi, D.; Bria, E.; Cuppone, F.; Ciuffreda, L.; Pino, M. S.; Gelibter, A.; Tortora, G.; Cognetti, F.; Milella, M. | |
| Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine | 2011 | Metro, G.; Foglietta, J.; Russillo, M.; Stocchi, L.; Vidiri, A.; Giannarelli, D.; Crino, L.; Papaldo, P.; Mottolese, Marcella; Cognetti, F.; Fabi, A.; Gori, S. | |
| Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy | 2011 | Vizza, E.; Pellegrino, A.; Milani, R.; Fruscio, R.; Baiocco, E.; Cognetti, F.; Savarese, A.; Tomao, Federica; Chen, C.; Corrado, G. | |
| Brain metastases from solid tumors. Disease outcome according to type of treatment and therapeutic resources of the treating center | 2011 | Fabi, A.; Felici, A.; Metro, G.; Mirri, A.; Bria, E.; Telera, S.; Moscetti, L.; Russillo, Michelangelo; Lanzetta, G.; Mansueto, G.; Pace, A.; Maschio, M.; Vidiri, A.; Sperduti, I.; Cognetti, F.; Carapella, CARMINE MARIA | |
| Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy. An italian, multicenter, randomized phase III trial | 2012 | Cognetti, F.; Ruggeri, E. M.; Felici, A.; Gallucci, M.; Muto, G.; Pollera, C. F.; Massidda, B.; Rubagotti, A.; Giannarelli, D.; Boccardo, Francesco | |
| Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. Meta-analytical estimation and implications for therapeutic strategies | 2012 | Loupakis, F.; Cremolini, C.; Salvatore, L.; Schirripa, M.; Lonardi, S.; Vaccaro, V.; Cuppone, F.; Giannarelli, D.; Zagonel, V.; Cognetti, F.; Tortora, G.; Falcone, A.; Bria, E. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile